InsidersTradesSigma
BIOMERIEUX Stock: price and directors' dealings · France · AMF
Follow the BIOMERIEUX share price and the full insider trade history of the company, a listed issuer based in France. Shares trade on FR FR, under the authority of AMF. Operating in the Healthcare & Pharma sector, BIOMERIEUX has logged 75 insider filings. Market capitalisation: €8.2bn. The latest transaction was reported on 1 July 2026 (Cession). Among the most active insiders: Alexandre Mérieux. All data is free.
75
Insider Decl.
0
Thresholds
€248m
27 ops.
Buy Volume
€37m
16 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate BIOMERIEUX Hold (neutral), based on 14 analysts. Average price target: €84.76.
53Σ signal
Fundamental score
Ranked 5,033 of 25,443 companies
67.0
score / 100
Value63
Quality71
FCF yld5.5%
Earn yld4.8%
EV/EBITDA10.2x
ROE9.5%
Gross mgn57%
Net mgn9.8%
Debt/EBITDA0.5x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Last declaration on 1 July 2026
Declarations75 total
277,058 shares@ €118.45520.40% mcap100.0% of flowActionEuronext Paris2026DD1123840
779,245 shares@ €69.99720.64% mcap0.5% of flowActionmultiplaces2026DD1112483
Ideal exit: 25 Jan 2027 (T+270)
404,367 shares@ €71.9640.34% mcap0.3% of flowActionMultiplaces2026DD1112485
Ideal exit: 29 Jan 2027 (T+270)
404,367 shares@ €71.9640.34% mcap0.3% of flowActionMultiplaces2026DD1112471
Ideal exit: 29 Jan 2027 (T+270)
779,245 shares@ €69.99720.64% mcap0.5% of flowActionMultiplaces2026DD1112475
Ideal exit: 25 Jan 2027 (T+270)
2,299 shares@ €114.535642.8% of flowActions gratuitesEuronext Paris2025DD1057334
1,486 shares@ €114.5356100.0% of flowActions gratuitesEuronext Paris2025DD1057335
4,625 shares0Actions gratuitesHors plateforme de négociation2025DD1057274
Ideal exit: 6 Jun 2026 (T+270)
3,677 shares0Actions gratuitesHors plateforme de négociation2025DD1057289
Ideal exit: 6 Jun 2026 (T+270)
7,875 shares0Actions gratuitesHors plateforme de négociation2025DD1056992
Ideal exit: 5 Jun 2026 (T+270)
3,750 shares0Actions gratuitesHors plateforme de négociation2025DD1056994
Ideal exit: 5 Jun 2026 (T+270)
4,750 shares0Actions gratuitesHors plateforme de négociation2025DD1056998
Ideal exit: 5 Jun 2026 (T+270)
6,250 shares0Actions gratuitesHors plateforme de négociation2025DD1057001
Ideal exit: 5 Jun 2026 (T+270)
164 shares@ €91.8439.4% of flowActionEuronext Paris2025DD1049368
Ideal exit: 24 Mar 2026 (T+270)
100 shares@ €104.48100.0% of flowActionEuronext Paris2025DD1047028
167 shares@ €91.84100.0% of flowActionEuronext Paris2025DD1046712
167 shares@ €91.84100.0% of flowActionEuronext Paris2025DD1046633
113.31 shares@ €91.84100.0% of flowActionEuronext Paris2025DD1046554
2,152,868 shares@ €1,095.164822.8% of flowActions de Compagnie Mérieux AllianceHors plateforme de négociation2025DD1027996
2,152,868 shares@ €1,095.164822.8% of flowActions de CMAHors plateforme de négociation2025DD1027997
2,550 shares@ €117.40100.0% of flowActions gratuitesEuronext Paris2025DD1027571
5,741 shares@ €117.3096.3% of flowActions gratuitesEuronext Paris2025DD1024766
778,699 shares@ €906.83756.8% of flowActions de Compagnie Mérieux Alliance et de AME HoldingHors plateforme de négociation2025DD1013673
778,699 shares@ €906.83756.8% of flowActions de Compagnie Mérieux Alliance et de MHC HoldingHors plateforme de négociation2025DD1013681
778,699 shares@ €906.83756.8% of flowActions de Compagnie Mérieux Alliance et de APC HoldingHors plateforme de négociation2025DD1013686
25 of 75 declarations
About BIOMERIEUX
bioMérieux is a global benchmark in in vitro diagnostics, providing solutions that detect, identify and monitor infectious agents as well as other disease states. Founded in 1963 in Marcy-l’Étoile, near Lyon, within the industrial and scientific ecosystem established by the Mérieux family, the company was built around a long-term mission: improving public health through fast, reliable and accessible diagnostic tools. As a family-controlled listed company, bioMérieux has gradually expanded into a leading position across several diagnostic segments, supported by an extensive international commercial and industrial footprint. The group’s business model is anchored in four main pillars: microbiology, syndromic testing, industrial applications and point-of-care diagnostics. In microbiology, bioMérieux provides instruments, reagents and consumables used by hospital and private laboratories to analyze infections and antimicrobial resistance. In syndromic diagnostics, the BIOFIRE® platform enables the rapid identification of multiple pathogens from a single sample. The company also develops solutions for the food, pharmaceutical and cosmetics industries to help secure production lines and ensure microbiological quality control. Its portfolio also includes SPOTFIRE®, a point-of-care platform designed for decentralized testing and faster clinical decision-making. bioMérieux is widely recognized as a global leader in in vitro diagnostics, with particularly strong positioning in clinical microbiology and a meaningful presence in syndromic testing. In 2024, the company generated €3.98 billion in sales, delivering 10.3% organic growth, driven by BIOFIRE®, the ramp-up of SPOTFIRE® and resilient performance in microbiology. For fiscal year 2025, sales reached €4.07 billion, confirming the group’s ability to sustain profitable growth. The company operates worldwide, with activities across Europe, North America, Latin America and Asia-Pacific. Headquartered in Marcy-l’Étoile, bioMérieux relies on a global network of manufacturing sites, R&D centers and sales subsidiaries. Recent milestones include the accelerated rollout of SPOTFIRE®, targeted acquisitions aimed at strengthening rapid diagnostics capabilities, and the company’s presence in major French and European equity indices, reflecting both its scale and market visibility.
